Moving on to the common cold, caused by the rhinovirus, the UKHSA explains that symptoms develop gradually over a few days.

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw some participants achieving an 88.94% reduction in viral load. The Japanese ...